Compare AngloGold Ashanti Limited (AU) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AngloGold Ashanti Limited vs TG Therapeutics Inc — how do they compare? AngloGold Ashanti Limited trades at $77.51 (market cap $40.62B), while TG Therapeutics Inc trades at $55.26 (market cap $8.41B). The key difference: AngloGold Ashanti Limited is far larger — about 4.8× TG Therapeutics Inc's market cap, and AngloGold Ashanti Limited pays a 5.73% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| AU | TGTX | |
|---|---|---|
Market Cap | $40.62B | $8.41B |
Sector | Basic Materials | Health |
52-Week High | $128.26 | $59.06 |
52-Week Low | $46.25 | $26.39 |
Enterprise Value | $39.75B | $8.65B |
Dividend Yield | 5.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AngloGold Ashanti (AU) trades at $79.76, down 2.85% amid bearish technical signals. The stock shows strong fundamentals with 2025 revenue growth to $9.89B and net income of $2.64B, supported by a 31.11% net margin. Recent Q1 2026 earnings beat expectations at $2.52 EPS versus $2.27 forecast. Analyst consensus remains positive with a $118.60 price target, though technical indicators show selling pressure with support at $77-79 levels.
The outlook remains favorable given robust cash flow growth and geographic diversification, but faces risks from gold price volatility and recent technical weakness. With 64% analyst buy ratings and significant upside to price targets, the stock presents value opportunity for patient investors despite near-term bearish momentum.
TG Therapeutics (TGTX) trades at $55.01, down 3.69% today, with a bullish technical signal from moving averages and a consensus analyst rating of 'Buy' from 11 of 13 analysts. The company reported strong revenue growth to $616.29 million in 2025 and a net income of $447.18 million, though recent quarterly EPS misses and negative operating cash flow of -$24.77 million highlight volatility. Positive news includes Phase II trials for Briumvi in schizophrenia and Phase I success in myasthenia gravis, driving investor optimism.
Outlook: TGTX offers growth potential through pipeline expansion and robust sales guidance, but faces risks from clinical trial outcomes, cash flow challenges, and high valuation multiples. The stock's 70% year-to-date gain reflects high expectations, requiring careful monitoring of execution against earnings forecasts and regulatory milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AngloGold Ashanti Limited
Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.
Read more on AU →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
